👋 Hey, let’s get into it. The tech bros continue to solidify their position in biotech. Apparently building social networks, ride-sharing apps, and online marketplaces wasn't enough.

This week, Anthropic launched Claude Science, an AI workbench designed specifically for researchers. Think of it as a labmate that never sleeps, never complains about experiments running late, and somehow knows its way around genomics, proteomics, cheminformatics, and scientific publishing.

Whether this becomes the greatest productivity tool scientists have ever seen or the world's most expensive intern remains to be determined. Either way, AI's march into biotech just took another big step forward.

🧠 QuantumCell Licenses Alzheimer's Asset in Potential $2.2B Deal
A stealthy Danish biotech with an AI and quantum computing pitch just landed a potentially massive Alzheimer's program. QuantumCell licensed AlzeCure's NeuroRestore platform and lead asset ACD856 for $12 million upfront plus milestones that could exceed $2.2 billion. The small molecule is designed to boost neurotrophin signaling and improve cognition, with potential applications spanning Alzheimer's disease, depression, and other neurological disorders. The deal comes shortly after encouraging Phase 1b data and highlights continued investor appetite for neuroscience despite years of setbacks across the field.

💸 Ipsen Buys Memo Therapeutics in $796M Rare Disease Bet
Ipsen is spending like a company that refuses to wait for internal pipelines to mature. The French pharma agreed to acquire Switzerland's Memo Therapeutics for €200 million ($227M) upfront, with total deal value reaching €700 million ($796M). The centerpiece is potravitug, a Phase 2 antibody targeting BK polyomavirus-associated nephropathy in kidney transplant patients. There are currently no approved therapies for the condition, which can lead to transplant failure. Memo's broader antibody platform won't come with the acquisition and will instead remain with a newly formed company owned by existing shareholders.

🫍 Orca Bio Wins FDA Approval for First-of-Its-Kind Cell Therapy Tregzi
Orca Bio officially joined the commercial biotech ranks after securing FDA approval for Tregzi, a first-of-its-kind engineered cell therapy designed to improve outcomes for blood cancer patients undergoing stem cell transplants. The therapy restructures donor grafts to include regulatory T cells that suppress graft-versus-host disease while preserving anti-cancer activity. In clinical testing, 78% of patients receiving Tregzi were alive and free of chronic GVHD after one year compared with 38% receiving conventional transplants. Orca plans to launch the therapy at a wholesale acquisition cost of $428,000.

🤝 Boulevard Bio Pays $20M Upfront for $1.6B Autoimmune T-Cell Engager Deal
Deerfield-backed Boulevard Bio is making a sizable bet on autoimmune disease. The biotech licensed Metis TechBio's preclinical trispecific T-cell engager MTS-128 for $20 million upfront and up to $1.6 billion in milestones. Unlike traditional bispecific T-cell engagers, MTS-128 targets three undisclosed biological pathways simultaneously, potentially improving efficacy and safety. The asset was developed using Metis' AI-driven NanoForge platform and reflects the growing enthusiasm surrounding next-generation immune-modulating therapies as competition intensifies across autoimmune disease markets.

☎️ AI-Powered Business Calling Starting at $12/User
Easily manage users, intelligently monitor business interactions, and improve productivity with AI-powered business communications. Learn more

🧬 FDA Gene Therapy Leader Steps Down
Vijay Kumar is stepping down as acting head of the FDA's gene therapy office, adding another chapter to the agency's seemingly endless leadership reshuffling.

🤑 BridgeBio Raises $1B
BridgeBio secured up to $1 billion in preferred equity financing as it prepares multiple commercial launches beyond blockbuster hopeful Attruby.

🏭 Lonza Expands ADC Manufacturing
Lonza is boosting ADC production capacity in Switzerland while deepening its relationship with a major unnamed U.S. drugmaker.

📈 Abivax Shares Rebound 38%
Fresh safety data helped calm investor concerns around ulcerative colitis candidate obefazimod, sending shares soaring 38%.

🏆 AbbVie’s Epkinly Combo Scores Phase 3 Win
AbbVie and Genmab's Epkinly combo reduced progression risk by 60% in diffuse large B-cell lymphoma, amping up its competition with Roche.

🌍 Kimball Expands With $103M CDMO Deal
Kimball Electronics, an Indiana-based contract manufacturer, acquired CDMO Helvoet Polymer Technologies to expand manufacturing across Europe and India.

🎯 BeOne's Brukinsa Shows Promise in Mantle Cell Lymphoma
In first-line mantle cell lymphoma, the BTK inhibitor cut progression risk by 43%, further widening its lead over AstraZeneca's Calquence.

For years, pharma companies flocked to China because it was faster, cheaper, and increasingly capable of running sophisticated clinical trials.

Now Congress wants answers.

This week, the House Select Committee on China launched investigations into Merck and AbbVie while sending inquiries to Eli Lilly, Pfizer, and Bristol Myers Squibb over clinical trial activities conducted in China. Lawmakers are seeking information on trial sites, data security practices, and relationships with institutions located in regions like Xinjiang and at hospitals affiliated with China's military.

The concern extends beyond ethics. Committee Chair John Moolenaar argues that American biotechnology intellectual property could potentially flow into Chinese military-linked organizations through collaborative research efforts. While no wrongdoing has been alleged, lawmakers clearly view biotech as an emerging national security issue.

The timing isn't random. China's rise in drug development has been extraordinary. In 2015, the U.S. accounted for roughly 48% of global early-stage drug development programs while China sat near 8%. By 2024, the U.S. share had fallen to around 37% while China surged above 32%.

Dealmaking followed the science. Global pharma companies signed a record $138 billion worth of licensing deals involving Chinese drugmakers last year. What started as occasional partnerships has evolved into major strategic alliances that now sit at the center of many pharma pipelines.

Not everyone thinks restrictions are the answer. BIO CEO John Crowley and investors like RA Capital's Peter Kolchinsky have warned that overly aggressive limits could make U.S. biotech less competitive globally. Their argument is simple: banning American companies from accessing China's speed and efficiency doesn't automatically strengthen the U.S. ecosystem.

The debate is no longer whether China matters in biotech. It's whether Washington believes the industry's growing dependence has become a strategic vulnerability.

That's the number of biotech and pharma mergers & acquisitions announced during the first half of 2026. The total marks a major rebound from roughly 30 deals during the same period last year. Eli Lilly led the charge with nine acquisitions and more than $25 billion committed, while Gilead and GSK combined for another $28 billion. If the first six months are any indication, pharma executives have officially put their checkbooks back to work.

Here’s what biotech Redditors are talking about:

🤫 The Regulatory Affairs Cheat Code
A Reddit thread about regulatory affairs salaries quickly turned into a support group for underpaid scientists. One former research associate said they jumped from $78,000 in the lab to $115,000 in regulatory affairs while working remotely. The comments only escalated from there, with stories of postdocs nearly tripling their income after leaving the bench. Then came the reality check…wait until you find out about commercial salaries, med device and pharma reps with successful territories, and high-yield products that can clear surgeon salaries. The consensus was simple: science skills transfer surprisingly well into regulatory work, and the compensation often comes as a shock to people who spent years believing lab salaries were normal.

🚚 Remember When Pharma Paid You to Move?
A discussion about relocation packages quickly became a nostalgia thread for biotech's boom years. Multiple Redditors highlighted Gilead's legendary relocation benefits, including home-buying assistance, closing costs, moving services, and six-figure package values in some cases. While many agreed those days are fading as companies tighten budgets, the thread felt like biotech veterans swapping stories about a time when recruiters practically begged candidates to relocate. The modern hiring market, apparently, is a little less generous.

🐂 AstraZeneca Settles Texas Kickback Lawsuit
AstraZeneca will pay $34 million to resolve allegations that free nursing services acted as illegal inducements for Medicaid-covered prescriptions.

🤖 Haleon Signs Microsoft AI Deal
Consumer health giant Haleon signed a five-year agreement to deploy Microsoft's AI tools across operations, supply chains, and commercial teams.

🥊 Amgen’s Tavneos Takes Another Hit
The New England Journal of Medicine retracted Tavneos' pivotal study as FDA pressure continues to mount against the rare disease drug.

🐝 Beeline Medicines Raises Another $126M, Bringing Series A to $426M
Most startups would take a victory lap after raising $300 million. Beeline Medicines raised another $126.3 million just two months later. Backed by Bristol Myers Squibb, Bain Capital Life Sciences, and a roster of heavyweight biotech investors, the company is building a portfolio of autoimmune and inflammatory disease therapies led by lupus candidate afimetoran. The management team previously helped guide SpringWorks through FDA approvals and a multibillion-dollar acquisition, giving investors confidence that this hive may be producing more than just buzz.

❤️ July 2, 2001 - The First Fully Self-Contained Artificial Heart
On this day in 2001, surgeons at Jewish Hospital in Louisville implanted the world's first fully self-contained artificial heart into 59-year-old Robert Tools. Unlike earlier devices, the AbioCor required no external tubes or wires, dramatically reducing infection risks. Doctors hoped the titanium-and-plastic heart might keep Tools alive for 60 days. He survived 151. The procedure marked a major leap forward in bioengineering and showed that replacing a failing human heart with a machine was no longer science fiction. For today's biotech innovators, it's a reminder that impossible breakthroughs often start as experimental longshots.

Thinking back to Claude Science, AI companies keep assuring us that artificial intelligence isn't here to take our jobs. It's here to help us do our jobs better.

Which sounds reassuring right up until your new AI labmate starts sending productivity reports to management.

"Jerry spent 18 minutes discussing fantasy football and used the bathroom four times today. I analyzed 4.2 million protein structures and drafted three manuscripts."

The future may not involve robots replacing scientists. It may involve scientists explaining themselves to robots, which somehow feels worse.

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,200+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.